Related Experiment Video

Updated: Jul 19, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

The use of inactivated influenza vaccine in children

Peter F Wright1

  • 1Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA. peter.wright@vanderbilt.edu

Seminars in Pediatric Infectious Diseases
|October 24, 2006
PubMed

Insights

Influenza poses a significant risk to young children, similar to the elderly. Current strategies now recommend trivalent inactivated influenza vaccines (TIVs) for children aged 6 to 59 months.

Area of Science:

  • Pediatrics
  • Immunology
  • Public Health

Background:

  • Influenza virus infections represent a substantial global health burden, particularly in vulnerable populations.
  • The impact of influenza on children under five years old is comparable to that observed in the elderly population.
  • Evolving epidemiological data necessitates adjustments in influenza vaccination strategies.

Purpose of the Study:

  • To review the safety and immunogenicity of trivalent inactivated influenza vaccines (TIVs) in pediatric populations.
  • To assess the efficacy of TIVs in preventing influenza illness in young children.
  • To outline current recommendations for TIV administration and dosage in children aged 6 to 59 months.

Main Methods:

  • Literature review of studies evaluating TIV safety, immunogenicity, and efficacy in children.
  • Analysis of current guidelines and recommendations from public health organizations.
  • Examination of data on vaccine administration schedules and appropriate pediatric dosing.

Main Results:

  • Trivalent inactivated influenza vaccines (TIVs) demonstrate a favorable safety profile in children.
  • Immunogenicity studies indicate robust antibody responses following TIV vaccination in the target pediatric age group.
  • Clinical efficacy data supports the use of TIVs in reducing influenza-related morbidity in young children.

Conclusions:

  • Influenza vaccination is a critical public health intervention for children aged 6 to 59 months.
  • Updated vaccination strategies should incorporate TIVs for this age group due to significant disease impact.
  • Further research may refine optimal dosing and administration protocols for pediatric influenza immunization.

More Related Videos

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers06:34

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection05:21

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection

Published on: August 14, 2019

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...